Stage 2 Breast Cancer After Radiation: What Comes Next — Hormone Therapy, HER2-Targeted Therapy, Subtype-Based Add-On Drugs and the Follow-Up Schedule

Reader question: radiation is done — what comes next, and why is every case different?

Short answer: finishing radiation is an important milestone, but many people still have adjuvant (add-on) treatment ahead, designed around their own pathology results.

A member of a patient group shared a video about her stage 2 breast cancer treatment, saying that radiation was finished and stressing that every case follows a different treatment path. This article summarizes the evidence on what usually follows radiation, which factors decide it, how long each drug class lasts, which side effects to watch and an evidence-based follow-up schedule. It does not assess any individual case and does not replace advice from your own treating doctor.

1. Why the next step after radiation differs from person to person

Short answer: stage 2 describes tumor size and spread, but the cancer subtype decides which drugs work, so doctors plan mainly from the post-surgery pathology report.

What stage 2 means

Stage 2 breast cancer generally means a tumor of about 2–5 cm without lymph node spread, a smaller tumor that has spread to 1–3 armpit lymph nodes, or a tumor larger than 5 cm without node spread, with no spread to other organs. This stage is treated with curative intent. Adjuvant therapy after surgery and radiation aims to eliminate any microscopic cancer cells left behind and to lower long-term recurrence risk.

Cancer subtypes: hormone receptors, HER2 and triple-negative

• Hormone receptor-positive (ER/PR-positive): the cancer uses estrogen to grow, so it responds to endocrine therapy. This is the most common type.
• HER2-positive: the cells carry too much HER2 protein. They grow fast but respond well to HER2-targeted drugs.
• Triple-negative (TNBC): no hormone receptors and no HER2, so endocrine and HER2-targeted drugs do not work. Treatment relies on chemotherapy and selected add-on drugs.

Pathology results that guide the decision

Beyond subtype, doctors look at the number of positive lymph nodes, tumor size, grade, Ki-67 (how fast cells divide), residual cancer after pre-surgery therapy, age, menopausal status and, in some people, BRCA testing. Two people with stage 2 disease can therefore have very different plans. Read more on pathology reports in After breast cancer surgery: wound care, reading the pathology report and planning adjuvant treatment.

Summary of trials and international guidelines to support discussion with your doctor, not a prescription (shown as cards on mobile).

2. Drugs that may follow radiation: endocrine therapy, targeted therapy and risk-based add-ons

Short answer: after radiation, treatment shifts from local therapy to whole-body drug therapy that lowers recurrence risk, and some of it lasts for years.

Endocrine therapy: tamoxifen, aromatase inhibitors and ovarian suppression

A meta-analysis of 20 trials and 21,457 women (EBCTCG 2011) found that in estrogen receptor-positive disease, about 5 years of tamoxifen lowered recurrence to 0.53 times in years 0–4 and 0.68 times in years 5–9, and cut breast cancer mortality by about one third over 15 years. For postmenopausal women, an analysis of 31,920 women (EBCTCG 2015) found that aromatase inhibitors such as anastrozole, letrozole and exemestane reduced recurrence by about 30% more than tamoxifen while the treatments differed, with 10-year breast cancer mortality of 12.1% versus 14.2%.

Premenopausal women at higher risk may also receive ovarian suppression with GnRH agonist injections such as goserelin or leuprolide. The SOFT/TEXT trials (Francis 2018) reported 8-year disease-free survival of 78.9% with tamoxifen alone, 83.2% with tamoxifen plus ovarian suppression and 85.9% with exemestane plus ovarian suppression, at the cost of more severe side effects such as menopausal symptoms and bone thinning.

Why some people take endocrine therapy for 10 years

An analysis of 62,923 women (Pan 2017) found that after stopping endocrine therapy at 5 years, distant recurrence continued at a steady rate every year up to year 20. The cumulative risk in years 5–20 was about 19% for tumors of 2–5 cm without node spread and about 26% with 1–3 positive nodes, groups that are common in stage 2. Doctors may therefore consider continuing therapy for 7–10 years in people at higher risk who tolerate the drugs.

HER2-targeted therapy: continue to complete about one year

An analysis of 7 trials and 13,864 women (EBCTCG 2021) found that adding trastuzumab to chemotherapy lowered recurrence to 0.66 times, reduced 10-year recurrence by 9.0 percentage points and lowered breast cancer death to 0.67 times. Total duration is usually about one year from the first dose given with chemotherapy, and it can continue during radiation. For people with residual cancer after pre-surgery therapy, the KATHERINE trial of 1,486 patients (von Minckwitz 2019) found that switching to trastuzumab emtansine (T-DM1) for 14 cycles raised 3-year invasive disease-free survival from 77.0% to 88.3%. During these drugs, doctors usually check heart function with echocardiograms at intervals, for example about every 3 months.

High-risk hormone receptor-positive disease: CDK4/6 inhibitors

The monarchE trial of 5,637 patients (Johnston 2020) studied hormone receptor-positive, HER2-negative disease with 4 or more positive nodes, or 1–3 nodes plus a tumor of 5 cm or more, grade 3 or Ki-67 of at least 20%. Adding 2 years of abemaciclib to endocrine therapy lowered the risk of invasive disease to 0.75 times, with 2-year invasive disease-free survival of 92.2% versus 88.7%. Common side effects are diarrhea, low white cells and fatigue, so regular blood tests are needed.

Triple-negative disease and BRCA mutations

Triple-negative does not automatically mean follow-up only. In people with residual cancer after pre-surgery therapy, the CREATE-X trial (Masuda 2017) found that oral capecitabine raised disease-free survival in the triple-negative group from 56.1% to 69.8% and overall survival from 70.3% to 78.8%; hand-foot redness and peeling was the most common side effect. In people with a BRCA mutation and high-risk disease, the OlympiA trial of 1,836 patients (Tutt 2021) found that one year of olaparib raised 3-year invasive disease-free survival from 77.1% to 85.9%. People who started the immunotherapy pembrolizumab with chemotherapy before surgery usually continue it after surgery to complete the plan.

Bone-protective drugs after menopause

An analysis of 18,766 women (EBCTCG 2015) found that in 11,767 postmenopausal women, bisphosphonates lowered bone recurrence to 0.72 times, lowered breast cancer death to 0.82 times and reduced fractures, but showed no anticancer benefit in premenopausal women. Have a dental check and treat any dental problems before starting, because these drugs can rarely cause jaw bone necrosis.

Taking the drugs consistently matters as much as choosing them

A cohort of 8,769 patients (Hershman 2010) found that 32% stopped endocrine therapy early within 4.5 years and only 49% completed it on schedule, with women under 40 at the highest risk of stopping. If side effects make daily life hard, tell your doctor: options include switching within the same drug class or treating joint pain and hot flashes. Do not stop on your own.

3. Follow-up schedule after treatment: what is checked and how often

Short answer: the core of follow-up is keeping scheduled visits, yearly mammograms and reporting new symptoms promptly, not frequent whole-body scans.

Visit frequency according to ASCO

The ASCO guideline (Khatcheressian 2013) recommends a history and physical exam every 3–6 months in years 1–3, every 6–12 months in years 4–5 and yearly after that. Patients should be told which symptoms may signal recurrence and should perform regular breast self-examination. People with a strong family history should be offered genetic counseling.

Mammograms after radiation

After breast-conserving surgery, the first post-treatment mammogram is done about 1 year after the diagnostic mammogram and at least 6 months after radiation ends, then yearly for both the treated and the other breast. After mastectomy, the remaining breast still needs a yearly mammogram. Ultrasound or MRI may be added for dense breasts, genetic risk or symptoms, as your doctor sees fit.

Why routine whole-body scans and tumor markers are not needed

ASCO does not recommend routine blood counts, chemistry panels, bone scans, chest X-rays, liver ultrasound, CT, PET-CT, MRI or tumor markers such as CEA and CA 15-3 in people without symptoms, because they do not help people live longer but do increase false alarms, repeat tests and anxiety. These tests have a role when symptoms appear, or when they are used to monitor side effects of a current drug.

Drug-specific monitoring

• Tamoxifen: yearly gynecologic exam; report abnormal vaginal bleeding right away. Avoid pregnancy and use non-hormonal contraception.
• Aromatase inhibitors: bone density testing before starting and at intervals; calcium and vitamin D as your doctor advises.
• HER2-targeted therapy: scheduled echocardiograms during treatment.
• Abemaciclib, capecitabine, olaparib: scheduled blood counts and liver tests.

Based on ASCO 2013 and drug side-effect monitoring; doctors may adjust it to individual risk (shown as cards on mobile).

4. Recovery after radiation: skin, arm swelling, drug side effects and daily life

Short answer: the period after radiation is about recovery — caring for the skin, moving the arm, exercising and managing side effects so the drugs can be completed.

Caring for irradiated skin

Irradiated skin is usually darkest and most irritated about 1–2 weeks after the last session, then improves over several weeks. Use fragrance-free moisturizer, wear loose cotton clothing and protect the area from sun for at least a year. Over the long term the breast may become slightly firmer or smaller. Read more in Post-radiation skin care and recovery.

Preventing arm swelling, and weight lifting

People who had armpit lymph node surgery plus armpit radiation have a higher risk of arm swelling. In a trial of 141 women who already had lymphedema (Schmitz 2009), slowly progressive supervised weight lifting did not worsen swelling, flare-ups fell from 29% to 14% and arm strength improved. Start light, wear a compression sleeve as your therapist advises, protect the arm skin from wounds and watch for swelling, heaviness, redness or heat. Exercises are in After breast and lymph node surgery: preventing lymphedema and shoulder exercises.

Managing endocrine therapy side effects

• Hot flashes: dress in layers and limit alcohol and very spicy food. If sleep is badly affected, doctors have non-hormonal options.
• Joint pain from aromatase inhibitors: regular exercise helps. If it persists, doctors may pause briefly or switch within the same class.
• Vaginal dryness: use hormone-free lubricants or moisturizers, and ask your doctor before using any hormone-containing product.
• Other medicines: always tell your doctor if you take certain antidepressants such as fluoxetine or paroxetine, which may weaken tamoxifen.

Exercise, weight and diet

About 150 minutes of aerobic activity a week plus strength training helps with fatigue and joint pain and helps control weight, which often rises during endocrine therapy. Read more in Weight gain during breast cancer treatment: causes and care. Normal dietary amounts of soy foods have not been linked to higher recurrence; see Can breast cancer patients drink soy milk? Herbs and supplements should never replace prescribed drugs, and your doctor should know about any you take.

Emotional care after main treatment ends

Many people feel relief when radiation ends, but also worry that the cancer will return, especially before follow-up visits. Talking with patient groups, returning to routines gradually and asking your doctor to explain the plan can ease that worry. If anxiety disrupts sleep or daily life, the Thai mental health hotline 1323 is available 24 hours a day.

Comparison of drug classes and care after radiation, using generic names only; doctors choose based on pathology and overall health (shown as cards on mobile).

Frequently asked questions (FAQ)

Questions people with stage 2 breast cancer and their families often ask after radiation ends.

I finished radiation for stage 2 breast cancer. What treatment comes next, and why is it different for everyone?

Treatment after radiation is driven mainly by the pathology report: hormone receptor (ER/PR) status, HER2 status, number of positive lymph nodes, tumor size, grade, Ki-67, whether cancer remained after pre-surgery therapy, age, menopausal status and BRCA status. Hormone receptor-positive cancers usually get several years of endocrine therapy, HER2-positive cancers usually continue targeted therapy to complete about one year, and triple-negative cancers may get add-on drugs only when residual disease or a BRCA mutation is present. Two people with stage 2 disease can therefore have very different plans.

How many years does hormone therapy last, and what are the side effects?

The standard is at least 5 years, and people at higher risk, such as those with a larger tumor or positive nodes, may continue for 7 to 10 years, because a study of 62,923 women found that recurrence risk continued steadily up to year 20 after stopping at 5 years. Tamoxifen can cause hot flashes, vaginal discharge, blood clots and a small rise in uterine cancer in women over 55. Aromatase inhibitors can cause joint pain, bone thinning and more fractures. Most side effects can be managed, so talk to your doctor before stopping.

How do tamoxifen and aromatase inhibitors differ, and which is used before menopause?

Tamoxifen blocks the estrogen receptor on cancer cells and works before or after menopause. Aromatase inhibitors such as anastrozole, letrozole and exemestane reduce estrogen made in fat tissue and are used after menopause. In 31,920 women they reduced recurrence by about 30% more than tamoxifen while the treatments differed. Premenopausal women at higher risk may receive ovarian suppression injections combined with an aromatase inhibitor or tamoxifen; the SOFT/TEXT trials reported 8-year disease-free survival of 85.9% and 83.2% versus 78.9% with tamoxifen alone.

If my cancer is HER2-positive, how much longer does targeted therapy continue after radiation?

Trastuzumab is usually given for about one year in total, counted from the first dose given with chemotherapy, and it can continue during radiation; the count does not restart after radiation. In 13,864 women, adding trastuzumab lowered recurrence to about 0.66 times and breast cancer death to about 0.67 times the risk without it. People with residual cancer after pre-surgery therapy may switch to trastuzumab emtansine (T-DM1) for 14 cycles, which raised 3-year invasive disease-free survival from 77.0% to 88.3%. Heart function is checked regularly during treatment.

With triple-negative breast cancer (TNBC), is follow-up the only thing left after radiation?

Not always. If no cancer remained after pre-surgery therapy, many people move to follow-up. If residual cancer remained, the CREATE-X trial found that oral capecitabine raised disease-free survival in the triple-negative group from 56.1% to 69.8%. People with a BRCA mutation and high-risk disease may receive olaparib for one year, which raised 3-year invasive disease-free survival from 77.1% to 85.9%, and people who started pembrolizumab with pre-surgery chemotherapy usually continue it to complete the plan. The choice depends on post-surgery pathology and genetic testing.

After treatment ends, how often is follow-up needed and what is checked?

ASCO recommends a history and physical exam every 3 to 6 months for the first 3 years, every 6 to 12 months in years 4 and 5, and yearly after that. After breast-conserving surgery, the first post-treatment mammogram is done about 1 year after the diagnostic mammogram and at least 6 months after radiation ends, then yearly. People on tamoxifen should have a yearly gynecologic exam, people on aromatase inhibitors should have bone density testing, and people on HER2-targeted therapy need scheduled heart checks.

Why does my doctor not order whole-body scans or tumor markers at every visit?

ASCO does not recommend routine blood counts, chemistry panels, bone scans, chest X-rays, liver ultrasound, CT, PET-CT, MRI or tumor markers such as CEA and CA 15-3 in people without symptoms, because studies have not shown that they help people live longer. They do produce false alarms, repeat testing and more anxiety. These tests are useful when symptoms appear, such as persistent bone pain, a chronic cough or weight loss, which should be reported right away without waiting for the next visit.

Can I lift things or exercise with the arm on the surgery side, and will it cause arm swelling?

Yes, once the wound has healed and your doctor agrees. In a trial of 141 women with breast cancer-related lymphedema, slowly progressive supervised weight lifting did not worsen swelling, lymphedema flare-ups fell from 29% to 14%, and arm strength improved. Start light, increase gradually, wear a compression sleeve as your therapist advises, and stop if the arm becomes swollen, heavy, red or hot.

Scientific mechanism

Summary by Asst. Prof. Dr. Norawit Raatpiboon:
surgery and radiation remove cancer in the breast and nearby lymph nodes, but a small number of cancer cells may enter the bloodstream before surgery and lie dormant in the bone marrow or other organs for years. Adjuvant therapy aims to eliminate or suppress these cells throughout the body.
In hormone receptor-positive cancer, estrogen binds its nuclear receptor and switches on genes that drive cell division. Tamoxifen competes for that receptor, while aromatase inhibitors block the enzyme that converts adrenal androgens into estrogen in fat tissue, the main estrogen source after menopause. Women whose ovaries still function therefore need ovarian suppression before these drugs can work. Dormant cells can reawaken slowly, which is why risk persists beyond year 5.
In HER2-positive cancer, excess HER2 protein sends constant growth signals. Trastuzumab binds HER2 to shut down signaling and recruit immune cells, and T-DM1 is the same antibody carrying a chemotherapy payload delivered directly into HER2-positive cells.
CDK4/6 inhibitors halt the cell cycle at the G1-to-S transition on which hormone receptor-positive cells depend heavily. Olaparib blocks the PARP DNA-repair enzyme, so cells lacking functional BRCA cannot repair DNA and die. Bisphosphonates reduce bone breakdown and make the bone marrow a less hospitable niche for cancer cells.

Related guides